Source comparison
PT-141 Versus Melanotan II
Melanotan II is the broader parent melanocortin agonist from which bremelanotide is derived; PT-141 is a metabolite (the C-terminal des-amide analogue) of Melanotan II. Both engage central MC4R and share the characteristic melanocortin effects of nausea, flush
This comparison does not assign a generated winner or score.
- Melanotan II is the broader parent melanocortin agonist from which bremelanotide is derived; PT-141 is a metabolite (the C-terminal des-amide analogue) of Melanotan II. Both engage central MC4R and share the characteristic melanocortin effects of nausea, flushing, and spontaneous erection, and both engage MC1R sufficiently to drive pigmentation. The key difference is one of development and intended use: Melanotan II is an unapproved, non-selective compound most associated with illicit tanning, whereas bremelanotide was refined and clinically developed as a defined, on-demand sexual-motivation agent and carries an approved human indication.[1] Research contexts that examine the two together are documented in the combined Melanotan II and PT-141 protocol reference.
- It is also worth situating both compounds against a third relative, afamelanotide (Melanotan I, marketed as Scenesse). Afamelanotide is a more MC1R-selective linear analogue that is approved for a rare light-sensitivity disorder, erythropoietic protoporphyria, and its selectivity for the pigmentation receptor is precisely why it is used for a skin indication rather than a sexual one. Comparing the three clarifies a general principle of this peptide class: the balance of receptor subtype activity determines the dominant clinical effect. A compound biased toward MC1R behaves like a pigmentation agent; a compound with meaningful central MC3R and MC4R activity behaves like a sexual-motivation agent; and a broad, non-selective compound like Melanotan II produces the full spectrum of melanocortin effects with correspondingly less predictability.
- Bremelanotide (PT-141)
- Central MC3R/MC4R active, also MC1R
- Sexual motivation
- FDA-approved (Vyleesi) for HSDD in women
- Melanotan II
- Broad, non-selective
- Tanning plus sexual and autonomic effects
- Unapproved
- Afamelanotide (Melanotan I)
- MC1R-selective
- Pigmentation
- Approved (Scenesse) for erythropoietic protoporphyria